Key points
- Pharmx Technologies reported a 2.7% increase in revenues to $7,737,000 for FY26.
- Net loss after tax was $1,826,000, a significant decrease from the previous year.
- Pharmx launched a new marketplace platform and completed a strategic alliance with Sigma Healthcare.
- The company aims to grow its gross transaction value to over $100 million within a year.
- Pharmx expects to reduce cloud platform costs by approximately 18% in FY27.
Full summary
Pharmx Technologies Limited reported a 2.7% increase in revenues to $7,737,000 for the year ended 30 June 2026. The company experienced a net loss after tax of $1,826,000, a significant decline from the previous year. Key highlights include the launch of a new marketplace platform and the completion of a strategic alliance with Sigma Healthcare, which positions Pharmx as a core technology infrastructure partner. The company aims to grow its gross transaction value to over $100 million within a year and expects to reduce cloud platform costs by approximately 18% in FY27. The financial statements were audited and an unmodified opinion was issued.
Guidance
FY27 gross transaction value target: over $100 million; cloud platform cost reduction: 18%
Outlook
Pharmx Technologies expects to build on strong momentum developed over the last two years, with a focus on growing volume-linked revenue and expanding the EBITDA margin over time.